Senseonics Launches Year-Long CGM in Europe, Eyes 30M Patient Market
Event summary
- Senseonics launched Eversense 365, its one-year implantable CGM, in Sweden on April 24, 2026, with planned launches in Germany, Spain, and Italy in the coming weeks.
- Eversense 365 doubles the sensor lifespan of the previous Eversense E3 model, extending monitoring from six months to a full year.
- The launch follows CE Mark approval in January 2026 and builds on commercial momentum in the U.S.
- Senseonics estimates the European market represents a total addressable market of over 30 million patients.
The big picture
Senseonics’ European launch represents a significant expansion for the company, moving beyond its established U.S. market. The introduction of a year-long CGM addresses a key pain point for patients and clinicians, potentially disrupting the traditional short-term CGM market. However, success hinges on navigating complex European regulatory and reimbursement landscapes, and demonstrating a clear clinical and economic advantage over existing solutions.
What we're watching
- Commercialization
- The speed of adoption across Germany, Spain, and Italy will be key to assessing the true market demand for a year-long implantable CGM.
- Reimbursement
- European reimbursement policies will significantly impact Eversense 365’s uptake, and the company’s ability to secure favorable coverage will be crucial for long-term success.
- Integration
- The success of the integration with Sequel Med Tech’s automated insulin delivery system will determine if Eversense can become a central hub for diabetes management.
Related topics